| Zaja, Francesco |
NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), Klinikum der Universitaet Muenchen | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma |
|
|
| Recruiting | 3 | 200 | Europe | R-pola-mini-CHP, R-mini-CHOP | Nordic Lymphoma Group, Roche Pharma AG | DLBCL, Diffuse Large B Cell Lymphoma | 02/23 | 02/26 | | |
NCT04168502: Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML |
|
|
| Recruiting | 3 | 414 | Europe | Glasdegib, Gemtuzumab Ozogamicin | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 04/23 | 04/27 | | |
| Recruiting | 3 | 400 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 10/23 | 04/27 | | |
|
|
|
|
|
|
|
|
|
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/24 | 06/24 | | |
|
|
|
| Not yet recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi ONLUS | Follicular Lymphoma | 07/28 | 07/30 | | |
| Active, not recruiting | 2 | 22 | Europe | Venetoclax, ABT-199/GDC-0199 | Fondazione Italiana Linfomi ONLUS | T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory | 03/20 | 12/22 | | |
|
FIL_KLIMT, NCT03891355: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL |
|
|
| Active, not recruiting | 2 | 16 | Europe | Carfilzomib, Lenalidomide, Dexamethasone | Fondazione Italiana Linfomi ONLUS | Mantle Cell Lymphoma | 12/20 | 09/22 | | |
NCT04251065: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH |
|
|
| Active, not recruiting | 2 | 8 | Europe | Daratumumab, Darzalex | Fondazione Italiana Linfomi ONLUS | Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma | 12/21 | 11/22 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Recruiting | 2 | 90 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi ONLUS, Janssen-Cilag S.p.A. | DLBCL | 02/23 | 02/25 | | |
MALIBU, NCT03697512: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas |
|
|
| Recruiting | 2 | 175 | Europe | Ibrutinib, Rituximab | International Extranodal Lymphoma Study Group (IELSG) | Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma | 06/24 | 06/27 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 56 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C)) | Fondazione Italiana Linfomi ONLUS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 02/25 | 02/27 | | |
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy |
|
|
| Recruiting | N/A | 15 | Europe | Venetoclax, Azacitidine, Decitabine | Ospedale Maggiore Di Trieste | Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax | 09/20 | 09/20 | | |
| Recruiting | N/A | 12 | Europe | Immune checkpoint inhibitor, radiotherapy | Ospedale Maggiore Di Trieste | Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy | 09/20 | 09/20 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 04/22 | 04/22 | | |
|
|
|
| Recruiting | N/A | 861 | Europe | Observation | Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation | Idiopathic Thrombocytopenic Purpura | 07/23 | 07/23 | | |
